Rania El-Botty

6PUBLICATIONS
72CO-AUTHORS
Cancer geneticsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 07, 2025
ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.

Francesca Bonechi, Marina Bacci, Nicla Lorito

|Feb 11, 2025
Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.

William C Reinhold, Elisabetta Marangoni, Fathi Elloumi

|Feb 28, 2024
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer.

Marina Bacci, Nicla Lorito, Alfredo Smiriglia

|Jul 14, 2023
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.

Rania El-Botty, Ludivine Morriset, Elodie Montaudon

|Feb 21, 2020
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

Florence Coussy, Rania El-Botty, Sophie Château-Joubert

Pageof 1